Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An eye in the middle of a magnifying glass. Industry Insights Seminar Series logo. Hosted by University of Oxford Medical Sciences Division Business Partnerships Office logo. Sponsored by BioEscalator University of Oxford logo.

Title:  Gene Therapy - Coming of Age

Speaker: Yatish Lad, Vice President, Head of Early Development

Abstract/speaker bio: Oxford Biomedica is a leading, fully integrated, cell and gene therapy group. They have built a sector-leading lentiviral vector delivery system, LentiVector® platform, which is leveraged to develop in vivo and ex vivo products both in-house and with partners. They have also created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases. They have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.

For further information on BridgeBio visit:




The Industry Insight Seminars provide a great opportunity to:

  • Increase awareness of commercial translation
  • Form connections between academics and industry 
  • Network with potential collaborators

These seminars are suitable for all scientists with some knowledge or interest in each topic area, from PhD students to PIs along with biotech, SMEs and Pharma companies.